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Glucocorticoids (GCs) are among the most widely used drugs in the world for the proven efficacy 
in the treatment of a variety of diseases, mainly chronic respiratory, autoimmune and neoplastic 
disorders [1]. It is estimated that approximately 1% of the Western world receives prolonged 
therapy with synthetic GCs, resulting in a supraphysiological exposure [1]. During GC treatment, 
patients often present with signs and symptoms of hypercortisolism, i.e., impaired glucose and 
calcium metabolism, hypertension and psychiatric disorders [2]. At the same time, GC withdrawal 
can induce psychiatric complaints [2] and physical discomfort (e.g., fatigue, lethargy, dizziness and 
weakness), suggestive for hypocortisolism (‘tertiary hypoadrenalism’) [3]. About 2–60% of adults 
treated with high GC doses develops psychiatric disturbances, ranging from mood alterations to 
overt psychosis [2, 4–6], usually recovering within 6 weeks after treatment cessation. The risk 
largely depends on GC dose (high risk of psychosis in patients receiving ≥40  mg/day of 
prednisone, or equivalents), rapidity of dose changes and, to a lesser extent, advanced age, 
intercurrent illnesses, female gender and history of psychiatric disorders [3–6]. Psychosis could 
depend in part to the anticholinergic properties of GCs, accelerating the production of tyrosine 
hydroxylase and dopamine β-hydroxylase—which, in turn, leads to an increased serum 
catecholamine activity and altered serotonergic and somatostatin activity—and the GABA agonism, 
exerted through the binding to GABA-A-receptor complex [2, 4–6]. Prevention strategies include 
the administration of the lowest possible GC dose, caution in treating patients at risk of psychiatric 
complications and avoidance of other drugs that increase circulating GC levels [5, 6]. A possible 
cause of GC-induced psychopathology is the suppression of GC secretion in physiological 
conditions, which follows a circadian rhythm, and in response to stress, since continuous exposure 
to synthetic GCs may cause desensitization and reduced responsiveness of the glucorticoid (GR) 
and mineralcorticoid receptor (MR)-dependent neuronal networks [7]. When synthetic GCs (like 
dexamethasone, prednisone and related steroids that have limited brain penetration) are used, the 
depletion of endogenous GC levels may cause a hypocortisolemic state in the brain—particularly 
lack of MR and episodic GR activation—with a consequent severe MR/GR imbalance [7]. At this 
purpose, replacement therapy with modified released GCs that better mimic the circadian pattern 
may be beneficial in restoring the MR/GR balance [7]. Patients treated with ≥20 mg/day of 
prednisone —or equivalent doses of other steroids— for ≥5 days are at risk of hypoadrenalism, 
while this condition is uncommon for shorter treatments, independently from the dose [3, 7]. 
Moreover, the risk seems higher in case of oral as compared to inhaled or topical administration [3]. 
However, because of the considerable variability in individual response to exogenous GCs, 
treatment dose and duration are not considered good predictors of the degree of HPA axis 
suppression [3]. Timing of HPA axis recovery after GC discontinuation is also largely variable. 
According to some studies, the higher is the GC dose, the longer is the time required for HPA 
recovery, independently from treatment duration; on the contrary, other studies suggested no 
correlations between the dose and duration of GC exposure and time of recovery [3, 7, 8]. In this 
context, it seems appropriate to consider the lesson learned from endogenous hypercortisolism. 
Indeed, in patients surgically treated for endogenous Cushing’s syndrome, signs and symptoms of 
hypocortisolism can persist even longer than one year after disease remission despite GC 
replacement therapy [8]. It is a paradigm of neuroendocrinology that the recovery of the HPA axis 
is a matter of time, although it generally occurs within months, rarely years. During this period, 
patients report signs and symptoms suggestive for GC deficiency, the so-called GCs withdrawal 
syndrome, even when the endogenous HPA axis function is apparently normal at biochemical 
evaluation [8]. A recent study demonstrated that HPA axis recovery was dependent on the etiology 
of Cushing’s syndrome, being shorter in ectopic ACTHdependent forms, intermediate in ACTH-
dependent pituitary disease and longer in adrenal Cushing’s syndrome [9]. The mechanisms 
underlying GCs withdrawal syndrome and HPA axis recovery are poorly understood, although a 
combination of physical and psychological dependence has been postulated, associated with 
secretory and functional alterations of various neurohormones—i.e., CRH, vasopressin and 
proopiomelanocortin peptide (POMC)—and central neurotransmitters—i.e., dopamine, 
noradrenaline and serotonin [8]. Hypothalamic production of CRH seems the timelimiting step for 
the HPA axis recovery. CRH levels in the cerebrospinal fluid of patients with Cushing’s disease are 
markedly decreased, suggesting a restraint in its brain production [10]. Moreover, an intact CRH 
system appears necessary for the adequate mesolimbic dopaminergic function. Therefore, CRH 
hyposecretion during GC withdrawal may contribute to anxiety and depression via inadequate 
stimulation of the dopaminergic neurons terminating in the nucleus accumbens [8, 10]. However, 
chronic postoperative CRH stimulation of the pituitary cannot shorten the period of GC replacement 
therapy [10], therefore suggesting the influence of other neurotransmitters pathways in HPA axis 
recovery. Actually, vasopressin production and release in hypothalamic neurons are reduced in 
chronic hypercortisolism [10]. Since vasopressin is involved in memory process, mood and 
concentration, it may be postulated that behavioral and mood changes occurring during both 
hypercortisolism and GC withdrawal may also reflect the effects of chronic altered vasopressin 
direct or CRH-mediated action on central neurons [8, 10]. On the other hand, symptoms of GC 
dependence and withdrawal could mimic those associated with opiates, since POMC derivative 
peptide secretion is also altered during hypercortisolism, and the recovery is gradual and parallel to 
HPA axis function [8, 10]. The central noradrenergic and dopaminergic systems may also 
contribute to the occurrence of mood disorders associated with both Cushing’s syndrome and GCs 
withdrawal syndrome [8, 10], since acute stress-induced HPA activation and dopamine release in 
the mesolimbic system promote behavioral activation toward appropriate stimulus response, while 
prolonged stress exposure inhibits the mesolimbic dopaminergic system, with failure of coping, and 
subsequent depressive manifestations [5, 10]. Moreover, panic behavior, anxiety and increased 
sympathoadrenal activity have been reported in the postoperative period in patients lacking of 
proper replacement treatment after successfully treatment for Cushing’s syndrome, subsiding after 
functional recovery of CRH and noradrenergic neurons [10]. The interplay between the central 
noradrenergic system and GCs in the pathogenesis of mood changes has still to be fully clarified, 
since both increased and decreased noradrenergic activity has been described in depression and in 
association with response to antidepressants [5, 6]. Based on these premises, and the difficulties 
commonly experienced by physicians when there is a need of reducing/ stopping GCs after 
prolonged treatments, due to the poor patient tolerance to the physical/psychophysical discomfort 
subsequent to the transient secondary hypocortisolism, we hypothesize some kind of GC 
‘addiction.’ In other words, we consider patient’s discomfort as a collection of signs and symptoms 
of GC abstinence. Under a clinical point of view, this hypothesis has two important consequences. 
First of all, the clinical impact of GC withdrawal has not to be underestimated. Second, its 
prevention and management represent a very challenging issue, since no valid treatment option can 
be offered in order to accelerate the recovery of HPA function. Indeed, ACTH administration would 
reexpose the patient to supraphysiological GC levels, so to persistent inhibition of the HPA axis, 
thus delaying, but not avoiding, the onset of GC withdrawal manifestations. The administration of 
neuroactive drugs, impinging on neurotransmitters pathways, could theoretically be able to re-
activate the CRH/AVP hypothalamic neurons inhibited by the prolonged exposure to synthetic GCs 
although this hypothesis remains to be demonstrated. On the other hand, based on the hypothesis 
that a more physiological replacement helps the restoration of the endogenous neuroendocrine 
mechanisms regulating the HPA axis function, modified released hydrocortisone appears the most 
suitable approach, among currently approved drugs for hypoadrenalism, to prevent signs and 
symptoms induced by deprivation of synthetic GCs, although clinical trials are mandatory before 
this treatment could be recommended.  
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